Overview

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.
Details
Lead Sponsor:
Bayer
Treatments:
Hormones
Radium Ra 223 dichloride
Succinylcholine